0001140361-24-035600.txt : 20240802
0001140361-24-035600.hdr.sgml : 20240802
20240802215326
ACCESSION NUMBER: 0001140361-24-035600
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240717
FILED AS OF DATE: 20240802
DATE AS OF CHANGE: 20240802
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Clemmer James C
CENTRAL INDEX KEY: 0001476700
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50761
FILM NUMBER: 241172983
MAIL ADDRESS:
STREET 1: COVIDIEN PLC
STREET 2: 15 HAMPSHIRE STREET
CITY: MANSFIELD
STATE: MA
ZIP: 02048
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ANGIODYNAMICS INC
CENTRAL INDEX KEY: 0001275187
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 113146460
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0531
BUSINESS ADDRESS:
STREET 1: 14 PLAZA DRIVE
CITY: LATHAM
STATE: NY
ZIP: 12110
BUSINESS PHONE: 5187981215
MAIL ADDRESS:
STREET 1: 14 PLAZA DRIVE
CITY: LATHAM
STATE: NY
ZIP: 12110
4
1
form4.xml
FORM 4
X0508
4
2024-07-17
0001275187
ANGIODYNAMICS INC
ANGO
0001476700
Clemmer James C
14 PLAZA DRIVE
LATHAM
NY
12110
true
true
President and CEO
false
Common Stock
2024-07-17
4
M
0
56279
0
A
690312
D
Common Stock
2024-07-17
4
F
0
28730
7.4
D
661582
D
Performance Right
2024-07-17
4
M
0
52378
0
A
Common Stock
52378
0
D
This acquisition of 56,279 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 21, 2021.
The exempt disposition of 28,730 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 21, 2021.
On July 21, 2021, the reporting person received a target grant of 52,378 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2022, 2023 and 2024 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 56,279 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.
/s/ Stephen A. Trowbridge, as Attorney in Fact
2024-08-02